$VTRS News

Last published 16h ago

16h agoVTRSViatris Named to Fortune's World's Best Workplaces™ List for Second Consecutive YearPR NewswireViatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that it has been named to Fortune's World's Best Workplaces™ list for...
17h agoBBIO VRTX GILD VTRS+1A Run of FDA Target Dates Fills the Biotech Calendar From Late November to Year EndPR NewswireBiotech Today News Commentary - The final weeks of 2026 carry a cluster of U.S. Food and Drug Administration (FDA) target action dates for...
1d agoVTRSViatris to Participate in Upcoming Investor ConferencesPR NewswireViatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that the Company will participate in fireside chats at three upcoming...
1w agoVTRSViatris Third Quarter 2026 Financial Results - VIATRIS INCEarnings Call Transcriptsgood morning and welcome to the veitris q3 2026 earnings call all participants will be in a listen-only mode should you need assistance please signal a conference specialist by pressing the star key followed by zero afte
1w agoVTRSViatris Inc - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 8.01 Item 9.01
1w agoVTRS PCRXViatris Announces Commencement of Tender Offer to Acquire Pacira BioSciences, Inc.PR NewswirePITTSBURGH, Oct. 30, 2026 /PRNewswire/ -- Viatris Inc. ("Viatris") (NASDAQ:VTRS), a global healthcare company, today announced that Peach Purchaser Sub Inc. ("Purchaser"), a wholly owned subsidiary of
3w agoVTRSViatris Receives U.S. FDA Approval for RYZUMVI® for the Treatment of PresbyopiaPR NewswirePITTSBURGH, Oct. 16, 2026 /PRNewswire/ -- Viatris Inc. (NASDAQ:VTRS), a global healthcare company, today announced that the U.S. Food and Drug Administration (FDA) has approved RYZUMVI® (phentolamine ophthalmic solution
1mo agoVTRS PCRXViatris Agrees to Acquire Pacira BioSciences, Advancing Its Innovative Medicines Strategy and Becoming a Leader in Non-Opioid Pain TherapiesPR NewswireAdds Two Marketed, Patent-Protected, High-Margin Medicines in the U.S., EXPAREL® and ZILRETTA®, and Expects to Expand the Products' Reach Across Selected Markets Within Its International Infrastructure Expands U.S.
1mo agoVTRSViatris to Report Third-Quarter 2026 Financial Results on November 5, 2026PR NewswireViatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced it will report third-quarter 2026 financial results on Thursday, November...
1mo agoVTRSViatris Recognized by Forbes as One of the World's Best Employers for the Sixth Consecutive YearPR NewswireViatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced it was named to Forbes' World's Best Employers list for the sixth...
1mo agoVTRSViatris Announces Approval of WAKIX® (Pitolisant) in Japan, a First-in-Class Treatment for Narcolepsy and Excessive Daytime Sleepiness Associated With Obstructive Sleep Apnea SyndromePR NewswireViatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that Japan's Ministry of Health, Labour and Welfare has granted approval...
3mo agoVTRSViatris Announces Quarterly DividendPR NewswireViatris Inc. (Nasdaq: VTRS) today announced that on August 3, 2026, its Board of Directors declared a quarterly dividend of $0.12 per share for each...
3mo agoVTRSViatris Receives U.S. FDA Approval for Gwyn Lo™, a Once-Weekly Contraceptive PatchPR NewswireViatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that the U.S. Food and Drug Administration (FDA) has approved Gwyn Lo™...
3mo agoSDZ-CH HIK-GB HIK-AE FME-DE+5Trump's generic drug tariffs: What they could mean for medicine prices, manufacturers and supplyCNBCTrump's generic drug tariff plan raises questions over prices, U.S. manufacturing and which drugmakers stand to gain or lose as details remain unclear.
4mo agoVTRSViatris to Report Second-Quarter 2026 Financial Results on August 6, 2026PR NewswireViatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced it will report second-quarter 2026 financial results on Thursday, August 6, ...
4mo agoVTRSViatris Announces Positive Top-Line Results from Phase 3 Study of VR-205 in Japanese Adults with Primary Immunoglobulin A NephropathyPR NewswireViatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced positive top-line results from a Phase 3 clinical trial evaluating the...
5mo agoVTRSU.S. FDA Accepts Viatris New Drug Application for Fast-Acting Meloxicam for the Treatment of Moderate-to-Severe Acute PainPR NewswireViatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review...
6mo agoVTRS2026 GLOBAL HEALTHCARE CONFERENCEVIATRIS INCEarnings Call TranscriptsAll right, morning, everybody. We're going to get going with our first company presenter at the B of A Annual Health Conference. My name is Jason Gerber. I cover pharma and biotech, and I'm pleased to be introducing our
6mo agoVTRSViatris to Present at the Bank of America Securities 2026 Healthcare ConferencePR NewswireViatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that the Company will present at the Bank of America Securities 2026...
6mo agoVTRSFirst Quarter 2026 Financial ResultsVIATRIS INCEarnings Call TranscriptsGood morning, and welcome to the Viatris First Quarter 2026 Earnings Call. All participants will be in listen-only mode. Should you need assistance, please signal a conference specialist by pressing the star key followed
6mo agoVTRSViatris Reports First-Quarter 2026 Financial ResultsPR NewswireViatris Inc. (Nasdaq: VTRS) today announced its first-quarter 2026 financial results. Executive Commentary "We delivered a strong first quarter,...
6mo agoVTRSViatris Announces Quarterly DividendPR NewswireViatris Inc. (Nasdaq: VTRS) today announced that on May 4, 2026, its Board of Directors declared a quarterly dividend of $0.12 per share for each...
6mo agoVTRSViatris Announces Chief Financial Officer TransitionPR NewswireViatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that Theodora "Doretta" Mistras, Chief Financial Officer, will depart the...
6mo agoVTRSViatris Announces Several Data Presentations on Investigational Low-Dose Estrogen Combined Hormonal Contraceptive Weekly Patch at the 2026 American College of Obstetricians and Gynecologists Annual Clinical & Scientific MeetingPR NewswireViatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that six abstracts on its investigational low-dose estrogen combined...
7mo agoVTRSViatris to Report First Quarter 2026 Financial Results on May 7, 2026PR NewswireViatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced it will report first quarter 2026 financial results on Thursday, May 7,...
7mo agoVTRSViatris Announces Multiple Data Presentations at the 2026 American Society of Cataract and Refractive Surgery Annual MeetingPR NewswireViatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that four abstracts will be presented at the American Society of Cataract...
7mo agoVTRSViatris Advances Innovative Portfolio with Approval of Effexor® in Japan for Adults with Generalized Anxiety Disorder (GAD)PR NewswireViatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that Japan's Ministry of Health, Labour and Welfare (MHLW) has approved...
7mo agoVTRSVIATRIS INVESTOR EVENTVIATRIS INCEarnings Call TranscriptsLadies and gentlemen, please welcome Head of Capital Markets, Beatrice Bill Schabluski. Good morning, everyone, and welcome to our Beatrice Investor Event. I'm Bill Schablouski, Head of Capitol Markets and Investor Relat
7mo agoVTRSViatris to Outline its Vision for Sustained Revenue and Earnings Growth Through 2030PR NewswireViatris Inc. (Nasdaq: VTRS) will host its Investor Event today, where members of the executive leadership team will outline the Company's strategic...
8mo agoVTRSViatris Reports Fourth-Quarter and Full-Year 2025 Financial ResultsPR NewswireViatris Inc. (Nasdaq: VTRS) today announced robust financial results for the fourth quarter and full year 2025. The Company also announced it has...
8mo agoVTRSViatris Maintains Dividend Policy for 2026 and Announces Quarterly DividendPR NewswireViatris Inc. (Nasdaq: VTRS) today announced that on February 23, 2026, its Board of Directors approved a 2026 dividend policy of 48 cents ($0.48) per ...
8mo agoVTRSFDA Accepts Viatris Supplemental New Drug Application for MR-141 (Phentolamine Ophthalmic Solution 0.75%) for the Treatment of PresbyopiaPR NewswireViatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review...
8mo agoVTRSMapi Pharma to Host Virtual KOL Event to Discuss Glatiramer Acetate Once a Month Depot for Primary Progressive Multiple Sclerosis, on March 3, 2026GlobeNewswireNESS ZIONA, Israel, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Mapi Pharma Ltd., a fully integrated, late-stage clinical development biopharmaceutical company focused on introducing innovative long-acting depot injectable
9mo agoVTRSViatris to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026, and Host Investor Event on March 19, 2026PR NewswireViatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced it will report fourth quarter and full year 2025 financial results on...
9mo agoVTRSMapi Pharma to Present New Safety and Efficacy Data from Glatiramer Acetate Depot Long-Acting Injection Phase II Study in Patients with Primary Progressive Multiple Sclerosis (PPMS) at ACTRIMS Forum 2026GlobeNewswireNESS ZIONA, Israel, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Mapi Pharma Ltd., a fully integrated, late-stage clinical development biopharmaceutical company focused on introducing innovative long-acting depot injectable
9mo agoVTRSViatris Appoints Matthew J. Maletta as Chief Legal OfficerPR NewswireViatris Inc. (Nasdaq: VTRS) announced today that Matthew J. Maletta has been appointed Chief Legal Officer (CLO), effective February 9, 2026. The...
9mo agoVTRS LXRXViatris Expands Innovative Portfolio in Cardiovascular Diseases with the Company's First Launch of Inpefa® (Sotagliflozin) for the Treatment of Heart FailurePR NewswireViatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced the launch of Inpefa® (sotagliflozin) in the United Arab Emirates (UAE),...
10mo agoVTRSViatris Appoints Lara Ramsburg as Chief People and Corporate Affairs OfficerPR NewswireViatris Inc. (Nasdaq: VTRS) announced today that Lara Ramsburg has been appointed Chief People and Corporate Affairs Officer. As part of Viatris'...
10mo agoVTRSMapi Pharma is Seeking New Partnerships for Long-Acting Depot Drugs of Peptides for Self AdministrationGlobeNewswireNESS ZIONA, Israel, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Mapi Pharma Ltd., a fully integrated, late-stage clinical development biopharmaceutical company focused on introducing innovative long-acting depot injectable
10mo agoVTRSViatris Provides Pipeline Update on Four Regulatory MilestonesPR NewswireViatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced four recent regulatory milestones spanning across all stages of its global...
11mo agoVTRSViatris to Present at the 44th Annual J.P. Morgan Healthcare ConferencePR NewswireViatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that the Company will present at the 44th Annual J.P. Morgan Healthcare...
11mo agoVTRSViatris Announces Agreement to Monetize its Equity Stake in Biocon Biologics LimitedPR NewswireViatris Inc. (Nasdaq: VTRS) today announced that it has entered into definitive agreements with Biocon Limited ("Biocon") for the sale of Viatris'...
11mo agoVTRSMapi Pharma is Seeking New Partnerships for Long-Acting Depot Drugs of Peptides for Self AdministrationGlobeNewswireNESS ZIONA, Israel, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Mapi Pharma Ltd., a fully integrated, late-stage clinical development biopharmaceutical company focused on introducing innovative long-acting depot injectable
11mo agoVTRSViatris to Participate in Upcoming Investor ConferencesPR NewswireViatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that the Company will participate in two upcoming healthcare conferences in ...
11mo agoSLGL VTRSSol-Gel Reports Third Quarter 2025 Financial Results and Provides Corporate UpdatesGlobeNewswireSol-Gel intends to pursue high-frequency BCC as an additional indication for its lead drug candidate SGT-610, which, if approved, could at least double the drug's commercial potentialIn September 2025, Sol-Gel announced
11mo agoVTRSEuropean study shows falling prices, rising costs and shortages - findings from independent study presented during World AMR Awareness Week by Viatris and Medicines for EuropePR NewswireAs World Antimicrobial Resistance (AMR) Awareness Week gets underway, the World Health Organization's 2025 Global Antibiotic Resistance Surveillance...
12mo agoVTRSViatris Recognized as One of the Fortune World's Best Workplaces™ in 2025PR NewswireViatris Inc. (Nasdaq: VTRS) today announced that it has been recognized as one of the Fortune World's Best Workplaces™ in 2025. The list of 25 global ...
1y agoVTRSViatris Reports Third Quarter 2025 Results and Updates 2025 Financial GuidancePR NewswireViatris Inc. (Nasdaq: VTRS) today reported strong third quarter 2025 financial results and updated full-year financial guidance. Executive Commentary ...
1y agoVTRSViatris Announces Quarterly DividendPR NewswireViatris Inc. (Nasdaq: VTRS) today announced that on November 3, 2025, its Board of Directors declared a quarterly dividend of $0.12 per share for...
1y agoVTRSLocus Biosciences Enters Research Collaboration to Develop Precision Antibacterial Therapies for Ophthalmic InfectionsBusiness WireCollaboration to develop engineered bacteriophage therapeutics targeting bacterial pathogens responsible for serious eye infections Locus Biosciences, Inc. ("Locus"), a clinical-stage biotechnology company developing